Treatment

Potential clinical meaningfulness of donanemab data

A call to review the CMS national coverage determination of anti-amyloid antibodies

ALZ-NET: examining novel approved treatments in the real-world

Topline donanemab results: most positive Phase III data to date

Next-generation anti-amyloid therapies: prioritizing selectivity

Anti-amyloid combination strategies in Alzheimer’s disease

Sex differences in Alzheimer’s disease: women’s journey, challenges, and implications

Targeting the immune system in Alzheimer’s disease

Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials

Expanding research into biomarkers for RPD differentiation

TREM2 as a target for disease modification in Alzheimer’s disease

Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials

TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab

Safety results of the Phase III gantenerumab GRADUATE I and II studies

Improving the next generation of anti-amyloid antibodies: prioritizing selectivity with PMN310

Symptomatic versus disease modifying treatments